General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Metastatic Urothelial Carcinoma
Last updated April 15, 2020
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Classic Hodgkin's Lymphoma
Last updated April 15, 2020
Status:
Concluded without agreement
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Advanced or Metastatic Breast Cancer
Last updated November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
Indivior UK Limited
Indication:
Opioid Use Disorder
Last updated April 8, 2020
Ibrance/fulvestrant (palbociclib/fulvestrant)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Advanced or Metastatic Breast Cancer
Last updated April 8, 2020
Triamcinolone Hexacetonide (triamcinolone hexacetonide)
Status:
Concluded with an LOI
Manufacturer:
Medexus Pharmaceuticals, Inc.
Indication:
Rheumatoid Arthritis
Last updated March 31, 2020
Segluromet (ertugliflozin/metformin hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Merck Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated March 31, 2020
Status:
Concluded without agreement
Manufacturer:
Merck Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated March 31, 2020
Orfadin Oral Suspension (nitisinone)
Status:
Concluded without agreement
Manufacturer:
Sobi Canada Inc.
Indication:
Hereditary Tyrosinemia Type 1
Last updated March 30, 2020
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
ROS1-positive advanced Non-Small Cell Lung Cancer
Last updated March 20, 2020